-
- 抗原 See all ABL1 抗体
- ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))
-
适用
- 人, 小鼠
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This ABL1 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Immunofluorescence (IF), Immunoprecipitation (IP)
- 品牌
- BD Pharmingen™
- 交叉反应
- 小鼠
- 产品特性
-
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. - 纯化方法
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- 免疫原
- Recombinant Mouse Abl Gag Fusion Protein
- 克隆位点
- 8E9
- 亚型
- IgG1
- Top Product
- Discover our top product ABL1 Primary Antibody
-
-
- 说明
-
Related Products: ABIN967389
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 0.5 mg/mL
- 缓冲液
- Aqueous buffered solution containing ≤0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Store undiluted at 4° C.
-
-
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy." in: Blood, Vol. 83, Issue 12, pp. 3629-37, (1994) (PubMed).
: "Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia." in: Hematologic pathology, Vol. 7, Issue 2, pp. 91-106, (1993) (PubMed).
: "Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients." in: Cancer research, Vol. 51, Issue 11, pp. 3048-51, (1991) (PubMed).
: "Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids." in: Oncogene research, Vol. 3, Issue 3, pp. 293-8, (1989) (PubMed).
: "Isolation of temperature-sensitive tyrosine kinase mutants of v-abl oncogene by screening with antibodies for phosphotyrosine." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, Issue 5, pp. 1345-9, (1987) (PubMed).
: "
-
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy." in: Blood, Vol. 83, Issue 12, pp. 3629-37, (1994) (PubMed).
-
- 抗原
- ABL1 (C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1))
- 别名
- Abl (ABL1 产品)
- 别名
- ABL antibody, JTK7 antibody, bcr/abl antibody, c-ABL antibody, p150 antibody, v-abl antibody, AI325092 antibody, Abl antibody, E430008G22Rik antibody, c-Abl antibody, ABL proto-oncogene 1, non-receptor tyrosine kinase antibody, c-abl oncogene 1, non-receptor tyrosine kinase antibody, Tyrosine-protein kinase abl-1 antibody, ABL1 antibody, Abl1 antibody, abl-1 antibody, abl1 antibody
- 背景
- The proto-oncogene c-abl was first isolated from the mouse genome as a gene with similarity to the v-abl oncogene of Abelson murine leukemia virus. The c-abl gene encodes a protein tyrosine kinase that is localized in the cytoplasm and nucleus. The c-abl protein shares several common features with other cytoplasmic tyrosine kinases, including the src-homology domains 2 (SH2) and 3 (SH3). The SH2 domain is believed to bind specifically to tyrosine residues of other proteins. The function of the SH3 domain is still unclear. Unique to the c-abl tyrosine kinase is a large C-terminal segment which seems to be essential for its biological function, since mice homozygous for a C-terminal deletion of c-abl have multiple defects at birth. The C-terminal fragment of c-abl contains a DNA-binding domain, and the DNA-binding affinity of this domain seems to be regulated by phosphorylation of critical serine/threonine residues. The c-abl proto-oncogene can be activated in a variety of ways. For example, in Philadelphia chromosome (Ph1)-positive leukemias the c-abl proto-oncogene on chromosome 9 becomes fused to the bcr gene on chromosome 22, and bcr-abl fusion proteins are produced. Ph1-positive cells express either the a-typical 210 kDa bcr-abl fusion protein or a smaller 185 kDa bcr-abl fusion protein. The bcr sequences activate the c-abl tyrosine kinase by deregulating its expression, and actin filament-binding function associated with c-abl is also activated. Expression of bcr-abl fusion proteins in vitro leads to transformation of pre-B lymphoid cells supporting their role as an oncogene. The phosphorylated form of c-abl is observed at ~145 kDa on SDS/PAGE. The 8E9 clone has been reported to react with an epitope in the tyrosine kinase domain of murine abl proteins [Wang et al.]. This antibody is routinely tested by western blot analysis.
- 分子量
- 145 kDa
- 途径
- Apoptosis, Regulation of Muscle Cell Differentiation, Platelet-derived growth Factor Receptor Signaling, Lipid Metabolism
-